Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.

A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials.

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

A new drug, 'MariTide,' developed by Amgen, has shown significant potential in treating obesity, with trial participants losing up to 16% body weight annually.

Amgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both ...

Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

If the drug is more broadly used in people with obesity and not just diabetes, those with higher body weights may see even ...

An experimental obesity drug has shown it can “substantially” reduce weight within a year, offering new hope for people with ...

Thousand Oaks, California Wednesday, June 25, 2025, 13:00 Hrs [IST] ...